{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.3","upperLimit":"63.3","value":"55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"}],"units":"Participants"}],"description":"A patient in the CIS cohort was judged to have achieved CR where urine cytology was reported as normal, atypical, degenerative, reactive, inflammatory, or nonspecific AND cystoscopy was reported as normal or with findings that did not include evidence of low-grade or high-grade recurrence. Bladder biopsy, if performed (not mandatory), demonstrated an absence of low-grade or high-grade recurrence.","dispersionType":"95% Confidence Interval","groups":[{"description":"CIS participants had at entry, confirmed by a pathology report: Carcinoma in situ (CIS) only or Ta/T1 highgrade disease with concomitant CIS AND were \"BCG unresponsive\" which referred to patients with highgrade NMIBC who were unlikely to benefit from and who did not receive further intravesical BCG. The term \"BCG unresponsive\" included patients who did not respond to BCG treatment and had a persistent high-grade recurrence within 12 months after BCG was initiated, and those who, despite an initial CR to BCG, relapsed with CIS within 12 months of their last intravesical treatment with BCG or relapsed with high-grade Ta/T1 NMIBC within 6 months of their last intravesical treatment with BCG.","id":"OG000","title":"Carcinoma in Situ"}],"paramType":"NUMBER","populationDescription":"Subjects analyzed for this endpoint represent subjects who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"12 Months","title":"Number of Patients With a Complete Response Rate Based on Patients With Carcinoma in Situ (CIS), With or Without Concomitant High-grade Ta or T1 Papillary Disease.","type":"PRIMARY","unitOfMeasure":"participants"}